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Inflammation is an essential process in many pulmonary diseases in which kinins are generated by protease action on kininogen,
a phenomenon that is blocked by protease inhibitors. We evaluated kinin release in an in vivo lung inflammation model in rats,
in the presence or absence of CeKI (C. echinata kallikrein inhibitor), a plasma kallikrein, cathepsin G, and proteinase-3 inhibitor,
and rCeEI (recombinant C. echinata elastase inhibitor), which inhibits these proteases and also neutrophil elastase. Wistar rats
were intravenously treated with buffer (negative control) or inhibitors and, subsequently, lipopolysaccharide was injected into their
lungs. Blood, bronchoalveolar lavage fluid (BALF), and lung tissue were collected. In plasma, kinin release was higher in the LPS-
treated animals in comparison to CeKI or rCeEI groups. rCeEI-treated animals presented less kinin than CeKI-treated group. Our
data suggest that kinins play a pivotal role in lung inflammation and may be generated by different enzymes; however, neutrophil
elastase seems to be the most important in the lung tissue context. These results open perspectives for a better understanding of
biological process where neutrophil enzymes participate and indicate these plant inhibitors and their recombinant correlates for
therapeutic trials involving pulmonary diseases.
1. Introduction
Lung diseases are responsible for the death of millions of
people every year. Inflammation is an essential component
of many of these disorders, such as pneumonia, asthma,
cancer, chronic obstructive diseases, acute lung injury, and
granulomatous lung diseases. In this scenario, kinins are
highly important in the physiopathology of lung inflamma-
tion. Once kinins are able to induce epithelial cells to release
bronchodilators and mucus secretion, they participate in
the airway smooth muscle contraction, leading to increased
microvascular leakage [1]. In vivo, the activation of the plasma
kallikrein-kinin system occurs when plasma prekallikrein
and the HK (high-molecular-weight kininogen) assemble
on endothelial cells [2]. Plasma prekallikrein is activated
in plasma kallikrein, which releases BK (bradykinin) from
HK that in turn stimulates B2 receptor. In the tissues,
KLK1 (kallikrein 1) hydrolyzes LK (low-molecular-weight
kininogen) to release Lys-BK, which is converted into BK
by aminopeptidase [3]. Lys-BK also acts on B2 receptor.
Although this represents themajor mechanism to BK release,
bioactive kinins are also generated from kininogens by the
action of other enzymes such as neutrophil proteases.
During the inflammatory process, neutrophils migrate
toward the site of inflammation and degranulate and release
proteolytic enzymes, such as NE (neutrophil elastase), Cat
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G (cathepsin G), and PR3 (proteinase 3). These enzymes are
involved in the degradation of extracellular matrix proteins
and act on a variety of plasma proteins [4, 5]. In addition,
human neutrophils are able to bind components of the
kallikrein-kinin system, such as kininogens [6] and plasma
prekallikrein [7]. Neutrophils are also able to express KLK1,
KLK4, KLK10, KLK13, KLK14, and KLK15 [8] and kinin
receptors [9].
Kininogen is also hydrolyzed byNE releasing E-kinin and
by PR3 liberating PR3-kinin. E-kinin does not induce smooth
muscle contraction but can bind to the B2-receptor after
processing at the carboxyterminus [10]. PR3-kinin is able to
bind and activate B1 receptor and exert a hypotensive effect
in vivo [11]. Despite kinins having an important role in the
regulation of pulmonary neutrophil recruitment, they act as
pro- or anti-inflammatory agents, depending on the stimulus
and animal model [12–16], and kinin release by proteases is
not fully understood in pulmonary inflammation.
One way to evaluate the action of proteases in different
physiopathological processes in vivo is using molecules that
can bind to them, such as proteolytic enzyme inhibitors.
These inhibitors are distributed among all living organisms,
including animals, plants, and microorganisms.
Several protease inhibitors extracted from plants have
been studied for their pharmacological potential. Consider-
ing the involvement of proteases in lung inflammation and
other lung pathologies, exogenous plant protease inhibitors
have been tested [17, 18].
In this context, we extracted and purified two different
inhibitors from seeds of C. echinata (Brazil-wood): (1) CeEI
(C. echinata elastase inhibitor), a NE, Cat G, PR3, and
plasma kallikrein inhibitor [19] and (2) CeKI (C. echinata
kallikrein inhibitor), a plasma kallikrein [20], Cat G, and PR3
inhibitor. CeKI also inhibits other proteases related to blood
coagulation and fibrinolysis and extends the partial activated
thromboplastin time without affecting the prothrombin time
[20].
In an edema model, using isolated perfused rabbit lungs,
CeEI reduced pulmonary arterial pressure and lung weight,
and CeKI was less effective [19]. In the present study, we
evaluated kinin release using a lung inflammation model in
rats in the absence or presence of protease inhibitors from C.
echinata seeds.
2. Material and Methods
Human plasma kallikrein, neutrophil Cat G, NE and PR3,
MeO-Suc-A-A-P-V-pNA,H-D-P-F-R-pNA, aprotinin,AEBSF
(4-(2-aminoethyl)benzenesulfonyl fluoride hydro-chloride),
E-64 (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)-
butane), and SBTI (soybean trypsin inhibitor) were obtained
from Merck KGaA (Darmstadt, Germany). Suc-A-A-P-F-
pNA,TPCK (N-p-tosyl-phenylalanine chloromethyl ketone),
o-phenanthroline, lisinopril, and LPS (lipopolysaccharide)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
BK and Tyr-BK were obtained from Peptide Institute Inc.
(Osaka, Japan) and 𝛾-globulin was obtained from Intergen
(Osaka, Japan). EDTA (ethylenediaminetetraacetic acid) was
purchased from Reagen (Rio de Janeiro, RJ, Brazil) and PEG
(polyethylene glycol 6000) from Quimesp (Sao Paulo, SP,
Brazil). Rabbit anti-BK antibody was prepared according to
the method described elsewhere [22]. ACE and Abz-F-R-
K(Dnp)-P-OH [23] were kindly supplied by Dr. Adriana K.
Carmona from the Department of Biophysics (UNIFESP,
Sao Paulo, SP, Brazil). CeKI was purified in our laboratory
according to Cruz-Silva et al., 2004; CeEI was purified in our
laboratory according to Cruz-Silva et al., 2013, and rCeEI was
cloned, expressed, and purified in our laboratory (Cruz-Silva
et al., manuscript in preparation). All other chemicals were
obtained from commercial sources andwere of the best grade
available.
This study was approved by the Ethics in Research
Committee of the Universidade Federal de Sao Paulo and
performed in accordance with the Guide for Care and Use of
Laboratory Animals (National Institute of Health Publication
number 86-23, Bethesda, MD, USA) and Lineas Directrices
Relativas al Alojamento y a los Cuidados de los Animales
(European Community Council, 86/609/CEE).
2.1. Inhibitory Constants. The inhibitory activities of rCeEI
and CeKI were tested on NE (1.0 nM) in 20mM Tris buffer
pH 7.5, those of Cat G (17 nM) in 50mM Tris buffer pH
8.0, those of PR3 (0.20 𝜇M) in 50mM Tris buffer, containing
50mM NaCl pH 7.5, those of plasma kallikrein (4.0 nM) in
20mM Tris buffer, containing 30mM NaCl pH 7.5, KLK1
(18 nM), and those of ACE (20 nM) in 20mM phosphate
buffer pH 7.3. The enzymes were preincubated for 10min at
37∘Cwith increasing amounts of rCeEI or CeKI.The residual
activity of the enzymes was determined with the hydrolysis
of appropriate substrates, namely, MeO-Suc-A-A-P-V-pNA
(0.20mM), Suc-A-A-P-F-pNA (0.30mM), MeO-Suc-A-A-P-
V-pNA (0.20mM), H-D-P-F-R-pNA (0.30mM), H-D-P-F-
R-pNA (0.30mM), and Abz-F-R-K(Dnp)-P-OH (10 𝜇M),
respectively. The ensuing 𝑝-nitroaniline (𝑝-NA) release was
followed at 405 nm in a SpectraCount plate reader (Packard
Instrument Co., Downers Grove, IL, USA). The hydrolysis of
the FRET (fluorescence resonance energy transfer) substrate
was followed by measuring the fluorescence at 𝜆em = 420 nm
and 𝜆ex = 320 nm in the same plate reader.
The equilibrium dissociation constant (𝐾𝑖) was deter-
mined by measuring the residual enzyme activity on sub-
strate hydrolysis. 𝐾𝑖 value was calculated by adjusting the
experimental points to the equation for a slow-tight binding
mechanism [24] using nonlinear fitting by GraFit, Erithacus
Software Ltd. (Horley, UK).
2.2. Lung Inflammation Model. For the lung inflammation
model, we used the methodology described by Duong et
al., 2001 [25], with some modifications. Male three-month-
oldWistar rats, weighing approximately 250 g, were obtained
from the Central Biotery at the Universidade Federal de Sao
Paulo.They had free access to food andwater and exposure to
alternate standardized light/dark periods of 14 and 10 h/day.
Animals were randomized into six groups: negative control
(𝑛 = 8), positive control (𝑛 = 6), 2.6mg CeKI (𝑛 = 6), 7.8mg
CeKI (𝑛 = 5), 0.78mg rCeEI (𝑛 = 5), and 2.6mg rCeEI (𝑛 =
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5). The animals were pretreated by the intravenous injection
(tail vein) of 50mM Tris buffer pH 8.0 (negative or positive
controls), CeKI (2.6 or 7.8mg), or rCeEI (0.84 or 2.6mg)
diluted in this same buffer.These concentrations were chosen
based on previous results with CeKI and CeEI in an isolated
lung edema rabbit model [19] and considering the rat blood
volume. After 20min, rats were lightly anesthetized with
ketamine and xylazine, and afterwards a small incision was
made (<0.3 cm); the same buffer (negative control) or 75 𝜇g
LPS/animal diluted in the samebuffer (positive control, CeKI,
and rCeEI groups) was injected via trachea directly into their
lungs. Six hours later, rats were once again anesthetized, a
thoracotomywas performed, and bloodwas collected directly
via the inferior cava vein by an incision in the presence of
34mM EDTA. To obtain plasma, blood was incubated on ice
for 60min followed by centrifugation at 270×g for 15min at
4∘C. Lungs were taken, cannulated, and washed with 10mM
phosphate buffer pH 7.4 (10mL). The washing solution was
collected and labeled BALF (bronchoalveolar lavage fluid).
Washed lungs were then homogenized in 10mM potassium
phosphate buffer (pH 7.4) and centrifuged at 3,000×g for
30min at 4∘C.
2.3. Protein Evaluation in BALF. Fifty 𝜇g of protein mixture
present in the BALF was applied in a sodium dodecyl sulfate
polyacrylamide electrophoresis (SDS-PAGE) 12% slab gels
according to the Laemmli method [26]; the protein bands
were stained with Coomassie brilliant blue and compared to
the molecular mass markers from Kaleidoscope Prestained
Standards (Bio-Rad Laboratories Hercules, CA, USA).
Total protein quantity was calculated according to Brad-
ford [27] using the Bio-Rad Protein Assay (Bio-Rad Lab-
oratories Hercules, CA, USA) following the manufacturer’s
instructions. The standard curve was performed with bovine
albumin solution.
2.4. Polymorphonuclear Neutrophils (PMNs) Counts in BALF.
Leukocyte recruitment to alveoli was determined in the BALF
in the presence of 0.40% Trypan Blue. Total and differential
leukocyte cells were counted manually with a Neubauer
chamber using an optical microscope.
2.5. Extraction of Kinins from BALF, Plasma, and Lung
Samples. The kinin extraction from BALF, plasma, or lung
was performed according to the method described by Shi-
mamoto et al., 1988 [28], with some modifications [29]. A
cocktail of protease inhibitors (24𝜇M SBTI, 10 𝜇M lisino-
pril, 10mM EDTA, 100 𝜇M TPCK, 10 𝜇M E-64, 5.0mM
o-phenanthroline, 1.0mM AEBSF, and 9.0 𝜇M aprotinin)
was added to BALF, plasma, or lungs, and samples were
centrifuged at 950×g for 15min at 4∘C. Next, ethanol was
added to the supernatant (2 : 1, v/v) and mixed for 30 s. After
centrifugation at 950×g for 15min at 4∘C, the supernatant
was transferred to another tube and vacuum-dried at 56∘C.
Water, acetone, and petroleum ether (1 : 2 : 7, v/v/v) were
added to the pellet and mixed for 30 s. The samples were
centrifuged at 950×g for 15min at 4∘C; the petroleum ether
phase with the lipidic content was discarded and the acetone-
aqueous phase was vacuum dried at 56∘C.
2.6. Radioimmunoassay for Kinins. The pellet obtained in
Section 2.5 was submitted to kinin radioimmunoassay
according to themethod described by Shimamoto et al., 1978,
with some modifications [21].
The experiment was performed twice and radiation val-
ues were converted into kinin released (pg) using a standard
curve.
2.7. ACE Activity in Lungs. Samples of lungs (5𝜇L), collected
in the absence of lisinopril, were maintained in 50mM Tris
buffer pH 7.4 containing 50mM NaCl for 5min at 37∘C
before the addition of the substrate Abz-F-R-K(Dnp)-P-OH
(10 𝜇M) in a final volume of 200𝜇l. Fluorescence changes
were monitored continuously for 30min at 𝜆ex = 320 nm
and 𝜆em = 420 nm in a SpectraCount plate reader (Packard
Instrument Co., Downers Grove, IL, USA). The slope of the
generated fluorescence signal was converted intomicromoles
of substrate hydrolyzed per minute based on a calibration
curve obtained from the complete hydrolysis of peptide
and adjusted for total protein quantity. This reaction was
performed in triplicate and lisinopril (10 𝜇M) was used to
confirm ACE activity.
2.8. Statistical Analysis. The results are shown as the mean
± SD of two different experiments performed in triplicate.
Statistical analyses were performed using one-way ANOVA
(analysis of variance) with the commercial program Graph-
PadPrismVersion 5 (GraphPad Software Inc., SanDiego, CA,
USA).
3. Results
3.1. Inhibitory Activity of Enzymes Involved in Lung Inflam-
mation. In previous works, we purified and characterized
two inhibitors from Caesalpinia echinata seeds: CeEI and
CeKI. Both inhibitors share similarities, according to Cruz-
Silva et al. [19, 20]. Comparing their partial N-terminal
sequence (30 amino acids’ residues), they are considered
members of Kunitz-type family, although they display 9
different amino acid residues between them. Although both
appear as a 20 kDa protein by SDS-PAGE, these inhibitors
present different retention times from C18 column, which
indicates that these inhibitors have variable hydrophobicity
degree. Finally, they display distinct inhibitory activity; CeKI
is able to inhibit plasma kallikrein [20] in a nanomolar range
and Cat G and PR3 are able to inhibit plasma kallikrein in
a micromolar range. On the other hand, rCeEI inhibits NE,
plasma kallikrein, and Cat G in a nanomolar range and PR3
in amicromolar range. Also, rCeEI blocks Cat G activity 320-
fold better than CeKI. Additionally, CeEI was more effective
than CeKI in reducing pulmonary edema in isolated rabbit
lung. CeEI also prevented hemodynamic (pulmonary artery
pressure) alterations in this model but CeKI did not have
any effect [19]. Therefore the major difference between these
inhibitors is Cat G and proteinase 3 inhibition. It is also
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Table 1: Specificities of rCeEI and CeKI on enzymes.
𝐾𝑖 (nM)
rCeEI CeKI
Neutrophil elastase 0.67 ± 0.05 n.i.∗
Neutrophil cathepsin G 6.54 ± 0.11 2100 ± 630
Neutrophil proteinase 3 3700 ± 67 2700 ± 205
Plasma kallikrein 1.00 ± 0.08 3.1 ± 0.1∗
Tissue kallikrein 1 n.i. n.i.
Angiotensin-converting enzyme n.i. n.i.
“n.i.”: no detectable inhibition.
∗Cruz-Silva et al., 2004.
NE (1.0 nM), Cat G (17 nM), PR3 (0.20 𝜇M), plasma kallikrein (4.0 nM),
KLK1 (18 nM), and ACE (20 nM) activities were determined by observing
the hydrolysis of the appropriate substrates, namely, MeO-Suc-A-A-P-V-
pNA (0.20mM), Suc-A-A-P-F-pNA (0.30mM), MeO-Suc-A-A-P-V-pNA
(0.20mM), H-D-P-F-R-pNA (0.30mM), H-D-P-F-R-pNA (0.30mM), and
Abz-F-R-K(Dnp)-P-OH (10 𝜇M), respectively. The enzymes were preincu-
bated in appropriate buffer for 10min at 37∘C with increasing amounts of
rCeEI or CeKI. The 𝑝-nitroaniline release was followed at 405 nm or the
fluorescencewasmeasured at𝜆exc =320nmand𝜆em =420 nmand𝐾𝑖 values
were calculated.
important to emphasize that both inhibitors did not block
tissue KLK1 and ACE activity. The inhibitory constants are
shown in Table 1.
3.2. Inflammatory PMN Counts. LPS is an endotoxin found
in the outer membrane of Gram-negative bacteria and it has
a potent proinflammatory activity. In order to verify LPS-
induced immune response, we evaluated PMN infiltration
into the alveolar space, counting leukocyte cells in BALF.
In BALF samples, we verified a 7.1-fold increase in PMNs
in the positive control compared to the negative control,
which was used as an indication of cell extravasation (Fig-
ure 1). All inhibitors were able to diminish the inflammatory
cell translocation to the BALF. CeKI (7.8mg and 2.6mg
groups) reduced by 4.1- and 3.0-fold, respectively, while rCeEI
(0.84mg and 2.6mg) caused a reduction in PMN amount
by 2.5- and 2.1-fold, respectively, indicating that the smaller
concentration was already responsible for the maximum
effect.
3.3. Kinin Release. Kinins were extracted by ethanol from
BALF, plasma, or lung in the presence of a cocktail of protease
inhibitors and submitted to kinin radioimmunoassay. In
BALF, kinin releasewas observed in all groups.TheLPS group
(positive control) showed high kinin content (15 pg/mg of
total protein), which corresponds to an augment of 13.5-fold
in comparison to the negative control.The inhibitors reduced
kinin release up to 9.0-fold, with no significant difference
between experimental groups (Figure 2(a)).
In plasma, kinin release was also detected in all groups.
Similarly, in the positive control, there was higher kinin
generation (0.1 pg/mg of total protein) than in the negative
control (7.5-fold). Accordingly, rCeEI reduced kinin release
by 50-fold and CeKI up to 4-fold (Figure 2(b)) in comparison
to LPS group. Therefore, kinin in plasma of rCeEI-treated
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Figure 1: PMN quantification in BALF. Rats were pretreated
intravenously with buffer (negative or positive controls), CeKI (7.8
or 2.6mg), or rCeEI (2.6 or 0.84mg). After 20min, they received
75 𝜇g LPS/animal (positive control and CeKI and rCeEI groups) or
buffer (negative control) injected via the trachea directly into their
lungs. Six hours later, lungs were collected and washed with buffer
(BALF). BALF (20𝜇L) was mixed with 0.4% Trypan Blue. Total and
differential leukocyte cells were counted manually with a Neubauer
chamber using opticalmicroscopy. ∗Significant difference compared
to negative control (𝜌 < 0.05). #Significant difference compared to
positive control (𝜌 < 0.05).
animals was lower than CeKI-treated animals by 13.5-fold in
average.
In lungs, we observed smaller kinin release (about fg/mg
of total protein) compared to BALF and plasma. In addition,
there was a significant reduction in kinin concentration only
in rCeEI-treated group compared to the positive control (2.3-
fold) (Figure 2(c)), confirming the importance of NE in the
process.
In order to understand the small presence of kinin in that
tissue, we evaluated the kininase activity of ACE.As expected,
a high ACE activity in the lung tissue, even in inhibitor-
treated animals, was observed (Figure 3). Nevertheless, a
significant reduction of ACE activity in rCeEI group was
showed. Despite the fact that the ACE activity was shown to
be smaller in rCeEI-treated animals, the kinin amount in this
groupwas also low,which indicates that this result wasmainly
due to lowered kinins by rCeEI compared to reduced ACE.
4. Discussion
The underlying pathophysiological mechanisms in lung
inflammation require a variety of disrupted homeostatic
events involving pulmonary endothelial and epithelial barrier
dysfunction, recruitment and neutrophil activation, and the
release of potent antimicrobial substances including oxidants
and proteases, such as NE, Cat G, and PR3. During inflam-
mation, these enzymes are able to cleave several cellular
substrates, and, under pathological conditions, they can
damage host tissues.
Here we analyzed the interplay between neutrophil
recruitment and protease release, as well as the
kallikrein-kinin system activation using LPS-induced
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Figure 2: Kinin release in BALF, plasma, and lungs. Rats were pretreated intravenously with buffer (negative or positive controls), CeKI
(7.8 or 2.6 mg), or rCeEI (2.6 or 0.84 mg). After 20min, they received 75 𝜇g of LPS/animal (positive control and CeKI and rCeEI groups)
or buffer (negative control) injected via the trachea directly into their lungs. Six hours later, blood was collected, BALF was obtained, and
lungs were extracted. Kinin was extracted from BALF (a), plasma (b), or homogenized lung (c) using a treatment with ethanol and then
water, acetone, and petroleum ether. For kinin quantification, a radioimmunoassay was performed according to Shimamoto et al., 1978, with
some modifications [21]. The experiment was performed twice and radiation values were converted into kinin (pg) using a standard curve.
∗Significant difference compared to negative control (𝜌 <0.05). #Significant difference compared to positive control (𝜌 < 0.05). &Significant
difference compared to CeKI-treated groups (𝜌 < 0.05).
lung inflammationmodel in rats and kinin detectionmethod
in BALF, plasma, and lungs.
PMN participation, primarily neutrophils, has been
described in many pulmonary diseases. In general, PMN
infiltration can be observed from 4 to 8 hours after LPS
or Gram-negative bacteria application or inhalation [30, 31].
Our results showed enhanced PMN recruitment into alveolar
space (about 7-fold) in LPS group suggesting that this model
mimics lung inflammation in which the native immune
response is activated. In contrast, inhibitor-treated animals
displayed smaller PMN extravasation, with similar behavior
to the negative control, indicating that rCeEI and CeKI were
efficient in reducing PMNmigration into the BALF.
The mechanism used by PMN to cross the endothelium
and enter the alveolar space is not completely clear; how-
ever leukocyte chemotaxis has been associated with PMN
migration [32]. Among chemoattractants, some are related to
protease activity. Cat G has been demonstrated as a potent
chemoattractant for monocytes and neutrophils in vitro [33],
as well as in patients with inflammatory disease, such as
rheumatoid arthritis [34]. So, it is reasonable to think that
neutrophil proteases could mediate chemotactic action for
PMN, which is in agreement with the lung inflammation
model used here. Additionally, our results with the pro-
tease inhibitors CeKI and rCeEI, which individually inhibit
kallikrein, PR3, and Cat G, suggested that the inhibition of
these enzymes is a key event for reducing PMN migration
into the alveolar space. Similarly, Oliveira et al. [35] showed
that BbCI, a NE-Cat G inhibitor extracted from Bauhinia
bauhinioides seeds, strongly inhibited leucocyte rolling, adhe-
sion, and migration, in an inflammation model induced by
carrageenan.
Regarding kinin generation, it is well know that this
peptide is involved in the major signs of inflammation, such
as pain, heat, redness, and swelling [36].
Using this LPS-induced lung inflammation model, we
detected different kinin amount in the analyzed compart-
ments (BALF, plasma, and lung), where they are believed to
6 Pulmonary Medicine
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Figure 3: ACE activity in lungs. Rats were pretreated intravenously
with buffer (negative or positive controls), CeKI (7.8 or 2.6mg),
or rCeEI (2.6 or 0.84mg). After 20min, they received 75 𝜇g of
LPS/animal (positive control and CeKI and rCeEI groups) or buffer
(negative control) injected via the trachea directly into their lungs.
Six hours later, lungs were extracted and homogenized. Samples
of lung (5 𝜇L) were maintained in 50mM Tris buffer at pH 7.4
containing 50mM NaCl for 5min at 37∘C before the addition of
the substrate Abz-F-R-K(Dnp)-P-OH (10𝜇M) in a final volume
of 200 𝜇L. Fluorescence changes were monitored continuously for
30min at 𝜆ex = 320 nmand 𝜆em = 420 nm.The slope of the generated
fluorescence signal was converted into micromoles of substrate
hydrolyzed per minute based on a calibration curve obtained from
the complete hydrolysis of peptide and adjusted for total protein
quantity. ∗Significant difference compared to negative control (𝜌 <
0.05). &Significant difference compared to CeKI-treated groups (𝜌 <
0.05).
mediate these inflammatory events. Considering all potential
sources of kinin and its high quantity in BALF (approximately
15 pg/mg of total protein in LPS group), it can be suggested
that this peptide could greatly be produced or be translocated
into the alveolar space. In plasma, kinin content was smaller
almost 150 times in comparison to BALF, while in lungs
kinin was detected in a fg scale (per mg of total protein),
which was slighter compared to BALF and plasma. Figure 4
summarizes the possible kinin-generating pathways in this
lung inflammation model.
Typically, kinin generation has been demonstrated in
plasma and attributed toHK proteolysis by plasma kallikrein.
However, this is not enough to explain the potential sources
of kinin in the current model. In this context, Idell et al.
[37] showed that kallikrein, prekallikrein, and factor XIa-like
activities as well as the HK antigen were found in BALF of
patients with ARDS (adult respiratory distress syndrome).
In addition, KLK1 and kinin were detected in BALF of
asthmatic subjects [38, 39] and antagonists of bradykinin B1
and B2 receptors showed modulatory effects in allergic and
immune complex-induced lung inflammation in mice with
neutrophil participation [14, 15]. These findings suggest that
the kallikrein-kinin cascade may be activated in the lungs
of patients during these pathological conditions, although
the interplay between kallikrein-kinin system and neutrophil
proteases (NE, Cat G, and PR3) in lung inflammation has
been poorly investigated.
In this respect, it was demonstrated that kininogen can be
also hydrolyzed by PR3 [11] and additionally facilitate kinin
system activation as it cleaves and inactivates the C1 inhibitor,
the major inhibitor of the kinin system [40]. The proteolytic
effect of PR3 on the C1 inhibitor, leading to its inactivation,
could result in uncontrolled kinin system activation, which
may, in turn, intensify the inflammatory response. Addition-
ally, although little is recognized about Cat G involvement
in kinin generation, it is already known that this enzyme is
able to form a complex with HK, which interferes in Cat G-
induced platelet activation without affecting its amidolytic
activity [41].
These evidences indicate that kinin could be generated by
different enzymes and scenarios; thus, to better discriminate
the action of these enzymes in this lung inflammationmodel,
we used two protease inhibitors extracted from C. echinata
seeds, CeKI and rCeEI, which differently inhibit plasma
kallikrein, PR3, Cat G, and NE. In BALF, both inhibitors
reduced kinin release up to 9.0-fold, with no significant
difference between experimental groups, indicating that a
combination of kinin-generating pathways was activated in
that compartment, and the inhibition of neutrophil enzymes
(NE, Cat G, and PR3) besides plasma kallikrein was respon-
sible for this result. Although the presence of kallikrein is
something unusual in BALF, our results regarding PMN
extravasation into alveolar space, in addition to a number of
evidences, support this suggestion, as neutrophils are able to
bind kininogen [6, 42] and plasma kallikrein [7].
In the plasma, kinin release was mainly reduced by rCeEI
up to 50-fold in comparison to LPS group,whichmay indicate
that NE play a central role in kinin generation in that model.
In the lungs, the smaller kinin release (about fg/mg of total
protein) compared to BALF and plasma was observed. It is
absolutely reasonable that the slighter kinin content in lungs
is a result of ACE activity, which is abundant on the surface
of lung endothelial cells [43] and it was shown to be very high
in the experiment for ACE activity detection. It is well known
that, during the few seconds of passage in the pulmonary
vascular bed, 80% to 95% of the biological activity of BK
was eliminated [44]. Accordingly, we propose that part of
the generated kinin in the lung was degraded by ACE during
their passage through the pulmonary vessels. However, if not
metabolized by ACE, kinin produced in the lungmight easily
enter the alveolus, contributing to the total amount of this
peptide in BALF (Figure 4).
In the lung tissue, similarly to other investigated compart-
ments, since there was a significant reduction in kinin con-
centration in rCeEI-treated group compared to the positive
control (2.3-fold), NE seems to be a central enzyme for kinin
generation. In fact, although kallikrein is a classical enzyme
for kinin release, it has been shown that kininogen can be
hydrolyzed by NE and the released E-kinin is subsequently
cleaved to produce BK [10, 45]. These evidences support our
data, which suggest that kinin may be released from kinino-
gen by neutrophil proteases, especially NE, as the treatment
of animals with rCeEI better attenuated this process.
Since protease inhibitors can access the alveolar microen-
vironment and bind to the major enzymes involved in
the inflammation processes, they appear as tools to allow
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Figure 4: Potential sources of kinin in LPS-induced lung inflammation model. Kinin may be generated in lung via kininogen hydrolysis
and is rapidly degraded by kininases. This peptide can be released into the alveolar space through distinct pathways: (a) in neutrophil-
bound kininogen cleavage by plasma kallikrein, (b) kininogen hydrolysis by NE and PR3, or (c) diffusion from the lung interstitium to the
alveolar space. In the plasma, pK, PR3, and NE all release kinin. Additionally, kinin might be exchanged between plasma, lung, and alveolar
space. K: kininogen (high-molecular-weight, low-molecular-weight, and/or T-kininogen); pK: plasma kallikrein; NE: neutrophil elastase;
PR3: proteinase 3; BALF: bronchoalveolar lavage fluid; LKT: leukotrienes; PAF: platelet activator factor.
a better understanding of the lung inflammation process
and its control. Also, they are good candidates for further
investigation using DNA recombinant approaches in order to
define the minimal dominium for inhibitory activity.
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